Recombinant Saccharomyces cerevisiae Mitochondrial phosphate carrier protein (MIR1)

What is the physiological role of MIR1 in Saccharomyces cerevisiae?

MIR1 serves as the primary transporter for inorganic phosphate into the mitochondrial matrix, which is essential for ATP synthesis. Genetic experiments have demonstrated that MIR1 is required for respiratory growth in S. cerevisiae, but interestingly, not for its fermentative growth . This selective requirement makes it particularly interesting for studying the transition between fermentative and respiratory metabolism.

The protein functions within the inner mitochondrial membrane, where it facilitates the exchange of phosphate for hydroxyl ions, maintaining phosphate homeostasis necessary for oxidative phosphorylation. Disruption of MIR1 function leads to impaired mitochondrial respiration and metabolic imbalances, including unusual accumulation of citrate in yeast cells .

How is recombinant MIR1 typically produced for research purposes?

Recombinant MIR1 protein is commonly produced using bacterial expression systems, particularly E. coli. The full-length gene sequence (encoding amino acids 1-311) is cloned into an appropriate expression vector with an N-terminal His-tag for purification purposes .

The expression process typically involves:

• Transformation of the expression construct into competent E. coli cells

• Induction of protein expression using IPTG or other inducers

• Cell lysis and extraction of proteins

• Purification using nickel affinity chromatography to isolate the His-tagged protein

• Further purification steps as needed

• Lyophilization to create a stable powder form

The final product is often provided as a lyophilized powder in a Tris/PBS-based buffer with trehalose (pH 8.0) to maintain stability. For experimental use, the protein should be reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL, with 5-50% glycerol added for long-term storage at -20°C or -80°C .

What experimental approaches can be used to study the impact of MIR1 inhibition on fungal metabolism?

Studying MIR1 inhibition impacts requires a multi-faceted approach:

Metabolomic Analysis:

• Employ LC-MS/MS to track metabolite changes following MIR1 inhibition

• Monitor citrate accumulation, which has been identified as a key metabolic signature of MIR1 inhibition

• Analyze flux through the TCA cycle using isotope-labeled substrates to identify metabolic bottlenecks

Oxygen Consumption Assessment:

• Measure mitochondrial oxygen consumption rates using oxygen electrodes or plate-based respirometry

• Compare respiration rates between normal and MIR1-inhibited conditions

• Evaluate the differential impact on respiratory vs. fermentative growth conditions

Genetic Approaches:

• Generate MIR1 knockout strains alongside chemical inhibition studies

• Create partial loss-of-function mutants to model different levels of inhibition

• Perform genetic suppressor screens to identify compensatory pathways

Structural Studies:

• Utilize purified recombinant MIR1 protein for binding studies with potential inhibitors

• Conduct protein crystallography to determine inhibitor binding sites

• Perform in silico docking studies to predict new inhibitor candidates

A comprehensive approach combining these methodologies provides the most complete understanding of how MIR1 inhibition affects fungal cellular physiology and identifies potential therapeutic targets .

How does the function of MIR1 in S. cerevisiae compare to phosphate carriers in pathogenic fungi, and what are the implications for antifungal development?

The mitochondrial phosphate carrier shows evolutionary conservation across fungal species while maintaining sufficient differences from human orthologues to represent a potential therapeutic target. ML316, a thiohydantoin compound, has demonstrated the potential of targeting MIR1 for antifungal development:

ML316 has demonstrated efficacy as a fungal-selective inhibitor of the mitochondrial phosphate carrier in drug-resistant Candida species at nanomolar concentrations. This inhibition results in diminished mitochondrial oxygen consumption and a unique metabolic catastrophe marked by citrate accumulation .

In mouse models of azole-resistant oropharyngeal candidiasis, MIR1 inhibition reduced fungal burden and enhanced azole activity, suggesting that targeting this protein could provide a valuable therapeutic strategy for addressing drug-resistant fungal infections .

What are the technical challenges in maintaining recombinant MIR1 protein stability and activity for functional assays?

Maintaining stability and functional activity of recombinant MIR1 presents several significant challenges:

Membrane Protein Solubility:

• As a transmembrane protein, MIR1 requires careful buffer optimization to maintain proper folding

• Detergent selection is critical for solubilization without denaturing the protein

• Reconstitution into liposomes or nanodiscs may be necessary for activity assays

Oxidation Sensitivity:

• Mitochondrial proteins often contain critical cysteine residues susceptible to oxidation

• Reducing agents like DTT or β-mercaptoethanol should be included in buffers

• Storage under nitrogen or argon atmosphere may help preserve activity

Freeze-Thaw Degradation:

• Repeated freeze-thaw cycles significantly reduce protein activity

• Working aliquots should be maintained at 4°C for up to one week

• For long-term storage, adding 50% glycerol and storing at -80°C is recommended

Functional Reconstitution:

• In vitro transport assays require reconstitution into artificial membranes

• Phosphate transport activity is highly dependent on proper orientation in the membrane

• Verification of function should include phosphate uptake assays using radioisotopes

To maximize stability and activity, the recombinant protein should be reconstituted in deionized sterile water to 0.1-1.0 mg/mL concentration, with glycerol added to a final concentration of 5-50%. Working aliquots should be maintained at 4°C, while long-term storage requires -20°C/-80°C conditions .

What expression systems and purification strategies yield the highest functional recovery of recombinant MIR1?

Optimization of expression and purification for MIR1 requires consideration of several key factors:

Expression Systems Comparison:

Purification Strategy Optimization:

• Affinity Chromatography: His-tag purification using nickel or cobalt resins (IMAC) provides highly specific initial capture

• Size Exclusion Chromatography: Removes aggregates and improves homogeneity

• Ion Exchange Chromatography: Further purifies based on charge properties

• Detergent Exchange: Critical for maintaining native-like structure

For maximum recovery of functional protein, the E. coli expression system with an N-terminal His-tag has proven effective, particularly when cells are grown at lower temperatures (16-18°C) after induction to slow expression and promote proper folding . The purified protein is then best stored as a lyophilized powder in Tris/PBS-based buffer with 6% trehalose at pH 8.0 to maintain stability .

What assays can be used to verify the functional activity of purified recombinant MIR1?

Several complementary assays can verify MIR1 functionality:

Phosphate Transport Assays:

• Liposome reconstitution assay: MIR1 is incorporated into liposomes, and 32P-labeled phosphate uptake is measured

• Proteoliposome counterflow assay: Pre-loaded proteoliposomes exchange internal phosphate for external radiolabeled phosphate

• Membrane potential-dependent transport: Assesses phosphate transport under various membrane potentials

Binding Assays:

• Isothermal titration calorimetry (ITC) to measure binding of phosphate and inhibitors

• Surface plasmon resonance (SPR) to determine binding kinetics

• Fluorescence-based assays using environment-sensitive probes

Structural Integrity Assessment:

• Circular dichroism (CD) spectroscopy to verify secondary structure

• Limited proteolysis to assess proper folding

• Thermal shift assays to determine protein stability

Inhibitor Responsiveness:

• Oxygen consumption measurements in reconstituted systems with and without inhibitors like ML316

• Monitoring metabolite changes (especially citrate accumulation) in response to MIR1 inhibition

• Competitive binding assays with known substrates and inhibitors

A comprehensive functional assessment should include at least one transport assay and one structural integrity assay to confirm both the activity and proper folding of the recombinant protein.

How can researchers design effective experiments to study the role of MIR1 in mitochondrial metabolism and fungal pathogenicity?

Designing effective MIR1 research experiments requires strategic planning:

Genetic Manipulation Approaches:

• CRISPR/Cas9 gene editing to create precise MIR1 mutations or knockouts

• Inducible expression systems to control MIR1 levels temporally

• Fluorescent protein tagging to monitor localization and expression levels

• Heterologous expression of MIR1 variants to assess functional conservation

Metabolic Analysis Pipeline:

• Stable isotope-resolved metabolomics to track phosphate incorporation into metabolites

• Real-time monitoring of oxygen consumption rates under various conditions

• ATP/ADP ratio measurements to assess energetic impact

• Metabolic flux analysis to identify pathway rerouting upon MIR1 inhibition

Pathogenicity Assessment Framework:

• In vitro growth assays comparing wild-type and MIR1-deficient strains under different carbon sources

• Host-pathogen interaction models to assess virulence

• Combination therapy testing with existing antifungals

• In vivo infection models with MIR1 inhibition (chemical or genetic)

Key Control Conditions:

• Comparing fermentative vs. respiratory growth conditions

• Assessing effects in azole-resistant vs. sensitive strains

• Testing in the presence of different phosphate concentrations

• Including human cell controls for toxicity assessment

Integration of data from these approaches provides a comprehensive understanding of MIR1's role in fungal physiology and pathogenesis. The ML316 inhibitor has already demonstrated potential in combination therapy approaches, reducing fungal burden and enhancing azole activity in mouse models of oropharyngeal candidiasis .

How can recombinant MIR1 be utilized in screening platforms for novel antifungal compounds?

Recombinant MIR1 offers several strategic advantages for antifungal drug discovery:

High-Throughput Screening Platforms:

• Fluorescence-based transport assays using purified MIR1 in liposomes

• Thermal shift assays to identify compounds that stabilize or destabilize the protein

• Competitive binding assays against known ligands like ML316

• Fragment-based screening to identify novel chemical scaffolds

Secondary Validation Assays:

• Oxygen consumption measurements in yeast mitochondria

• Metabolomic profiling focusing on citrate accumulation as a biomarker

• Growth inhibition assays comparing effects on respiratory vs. fermentative conditions

• Synergy testing with established antifungals

Comparative Assessment Framework:

The development of ML316, a thiohydantoin that kills drug-resistant Candida species at nanomolar concentrations through fungal-selective inhibition of MIR1, demonstrates the potential of this approach. This compound diminished mitochondrial oxygen consumption in respiring yeast, resulting in a metabolic catastrophe marked by citrate accumulation .

What research questions remain unresolved regarding the structure-function relationship of MIR1?

Despite significant progress, several critical knowledge gaps remain:

Structural Dynamics:

• High-resolution crystal structure of MIR1 has not been determined

• Conformational changes during transport cycle remain poorly understood

• Substrate recognition mechanisms and specificity determinants need clarification

• Role of specific amino acid residues in transport function requires further characterization

Regulatory Mechanisms:

• Post-translational modifications affecting MIR1 activity

• Interactions with other mitochondrial proteins in transport complexes

• Transcriptional and translational regulation under different metabolic conditions

• Turnover and degradation pathways controlling MIR1 levels

Comparative Biology:

• Functional differences between MIR1 in S. cerevisiae and pathogenic fungi

• Evolutionary adaptations in phosphate transport across fungal species

• Species-specific inhibitor selectivity determinants

• Compensatory mechanisms in response to MIR1 inhibition

Therapeutic Potential:

• Optimization of ML316 and derivative compounds for improved pharmacokinetics

• Resistance mechanisms that may emerge against MIR1 inhibitors

• Potential off-target effects on human phosphate carriers

• Synergistic combinations with existing antifungal classes

Addressing these questions will require integrated approaches combining structural biology, biochemistry, genetics, and pharmacology. The development of ML316 as the first identified Mir1 inhibitor has opened new avenues for research into this promising antifungal target .

What are the optimal storage and handling conditions for maintaining recombinant MIR1 stability?

Proper handling of recombinant MIR1 is critical for experimental reproducibility:

Storage Recommendations:

• Short-term storage (up to one week): 4°C as working aliquots

• Medium-term storage: -20°C with 50% glycerol

• Long-term storage: -80°C or as lyophilized powder

• Avoid repeated freeze-thaw cycles which significantly reduce activity

Buffer Composition:

• Tris/PBS-based buffer at pH 8.0

• Addition of 6% trehalose as a stabilizing agent

• 50% glycerol for frozen storage

• Consider adding reducing agents to prevent oxidation of sulfhydryl groups

Reconstitution Protocol:

• Briefly centrifuge the vial prior to opening

• Reconstitute in deionized sterile water to 0.1-1.0 mg/mL

• Add glycerol to 5-50% final concentration

• Aliquot for long-term storage to avoid repeated freeze-thaw cycles

Quality Control Indicators:

• Purity should be >90% as determined by SDS-PAGE

• Functional activity should be verified after extended storage

• Appearance should be clear without visible precipitation

• Occasional gentle mixing rather than vortexing is recommended

Following these guidelines will help maintain protein integrity and experimental consistency across studies using recombinant MIR1 protein .